nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—SLC31A1—Carboplatin—uterine cancer	0.265	0.482	CbGbCtD
Bortezomib—CYP1A1—Progesterone—uterine cancer	0.0435	0.0792	CbGbCtD
Bortezomib—CYP2C8—Medroxyprogesterone Acetate—uterine cancer	0.0379	0.069	CbGbCtD
Bortezomib—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.0265	0.0481	CbGbCtD
Bortezomib—CYP2C8—Progesterone—uterine cancer	0.0251	0.0457	CbGbCtD
Bortezomib—CYP2C19—Progesterone—uterine cancer	0.0211	0.0383	CbGbCtD
Bortezomib—PTGS1—Etoposide—uterine cancer	0.0195	0.0354	CbGbCtD
Bortezomib—CYP1A2—Progesterone—uterine cancer	0.0195	0.0354	CbGbCtD
Bortezomib—CYP2C9—Progesterone—uterine cancer	0.0175	0.0319	CbGbCtD
Bortezomib—CYP2D6—Progesterone—uterine cancer	0.016	0.0291	CbGbCtD
Bortezomib—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0154	0.028	CbGbCtD
Bortezomib—CYP2C8—Etoposide—uterine cancer	0.0112	0.0204	CbGbCtD
Bortezomib—CYP3A4—Progesterone—uterine cancer	0.0102	0.0185	CbGbCtD
Bortezomib—CYP1A2—Etoposide—uterine cancer	0.0087	0.0158	CbGbCtD
Bortezomib—CYP2D6—Doxorubicin—uterine cancer	0.00489	0.0089	CbGbCtD
Bortezomib—PSMB1—oviduct—uterine cancer	0.00471	0.0401	CbGeAlD
Bortezomib—CYP3A4—Etoposide—uterine cancer	0.00456	0.00829	CbGbCtD
Bortezomib—CYP3A4—Doxorubicin—uterine cancer	0.00311	0.00566	CbGbCtD
Bortezomib—CTSG—myometrium—uterine cancer	0.00275	0.0234	CbGeAlD
Bortezomib—PSMD1—myometrium—uterine cancer	0.00222	0.0189	CbGeAlD
Bortezomib—CTSG—uterine cervix—uterine cancer	0.00214	0.0182	CbGeAlD
Bortezomib—PSMA1—epithelium—uterine cancer	0.00207	0.0177	CbGeAlD
Bortezomib—PSMD2—myometrium—uterine cancer	0.00196	0.0167	CbGeAlD
Bortezomib—PSMB8—myometrium—uterine cancer	0.00195	0.0166	CbGeAlD
Bortezomib—PSMA1—renal system—uterine cancer	0.00192	0.0164	CbGeAlD
Bortezomib—CTSG—mammalian vulva—uterine cancer	0.00187	0.016	CbGeAlD
Bortezomib—PSMD1—uterine cervix—uterine cancer	0.00173	0.0147	CbGeAlD
Bortezomib—PSMB5—myometrium—uterine cancer	0.00172	0.0147	CbGeAlD
Bortezomib—PSMA1—uterus—uterine cancer	0.00171	0.0146	CbGeAlD
Bortezomib—PSMD1—smooth muscle tissue—uterine cancer	0.00168	0.0143	CbGeAlD
Bortezomib—PSMD1—decidua—uterine cancer	0.00164	0.014	CbGeAlD
Bortezomib—PSMD1—endometrium—uterine cancer	0.00156	0.0133	CbGeAlD
Bortezomib—PSMA1—female reproductive system—uterine cancer	0.00154	0.0131	CbGeAlD
Bortezomib—PSMD2—uterine cervix—uterine cancer	0.00153	0.013	CbGeAlD
Bortezomib—PSMB8—uterine cervix—uterine cancer	0.00152	0.0129	CbGeAlD
Bortezomib—PSMD1—mammalian vulva—uterine cancer	0.00151	0.0129	CbGeAlD
Bortezomib—PSMB1—myometrium—uterine cancer	0.00151	0.0128	CbGeAlD
Bortezomib—PSMD2—smooth muscle tissue—uterine cancer	0.00149	0.0127	CbGeAlD
Bortezomib—PSMB2—myometrium—uterine cancer	0.00147	0.0125	CbGeAlD
Bortezomib—PSMD2—decidua—uterine cancer	0.00146	0.0124	CbGeAlD
Bortezomib—CTSG—vagina—uterine cancer	0.00145	0.0124	CbGeAlD
Bortezomib—PSMB8—decidua—uterine cancer	0.00145	0.0123	CbGeAlD
Bortezomib—PSMD1—uterus—uterine cancer	0.00144	0.0123	CbGeAlD
Bortezomib—PSMD2—renal system—uterine cancer	0.00143	0.0122	CbGeAlD
Bortezomib—PSMA1—female gonad—uterine cancer	0.0014	0.0119	CbGeAlD
Bortezomib—PSMD2—endometrium—uterine cancer	0.00138	0.0118	CbGeAlD
Bortezomib—PSMB8—endometrium—uterine cancer	0.00137	0.0117	CbGeAlD
Bortezomib—PSMB5—uterine cervix—uterine cancer	0.00134	0.0114	CbGeAlD
Bortezomib—PSMD2—mammalian vulva—uterine cancer	0.00134	0.0114	CbGeAlD
Bortezomib—PSMB8—mammalian vulva—uterine cancer	0.00133	0.0113	CbGeAlD
Bortezomib—PSMB5—smooth muscle tissue—uterine cancer	0.0013	0.0111	CbGeAlD
Bortezomib—PSMB5—decidua—uterine cancer	0.00128	0.0109	CbGeAlD
Bortezomib—PSMD2—uterus—uterine cancer	0.00127	0.0109	CbGeAlD
Bortezomib—SLC31A1—myometrium—uterine cancer	0.00127	0.0108	CbGeAlD
Bortezomib—PSMB5—endometrium—uterine cancer	0.00121	0.0103	CbGeAlD
Bortezomib—PTGS1—oviduct—uterine cancer	0.00119	0.0101	CbGeAlD
Bortezomib—PSMD1—female gonad—uterine cancer	0.00118	0.01	CbGeAlD
Bortezomib—PSMB5—mammalian vulva—uterine cancer	0.00117	0.01	CbGeAlD
Bortezomib—PSMB1—uterine cervix—uterine cancer	0.00117	0.00999	CbGeAlD
Bortezomib—PSMD1—vagina—uterine cancer	0.00117	0.00996	CbGeAlD
Bortezomib—PSMD2—female reproductive system—uterine cancer	0.00115	0.00976	CbGeAlD
Bortezomib—PSMB2—uterine cervix—uterine cancer	0.00114	0.00975	CbGeAlD
Bortezomib—PSMB1—smooth muscle tissue—uterine cancer	0.00114	0.00971	CbGeAlD
Bortezomib—PSMB5—uterus—uterine cancer	0.00112	0.00953	CbGeAlD
Bortezomib—PSMB1—decidua—uterine cancer	0.00112	0.00952	CbGeAlD
Bortezomib—PSMB2—smooth muscle tissue—uterine cancer	0.00111	0.00947	CbGeAlD
Bortezomib—PSMB1—renal system—uterine cancer	0.0011	0.00935	CbGeAlD
Bortezomib—PSMB2—decidua—uterine cancer	0.00109	0.00929	CbGeAlD
Bortezomib—PSMB2—renal system—uterine cancer	0.00107	0.00912	CbGeAlD
Bortezomib—PSMB1—endometrium—uterine cancer	0.00106	0.00904	CbGeAlD
Bortezomib—PSMD2—female gonad—uterine cancer	0.00104	0.00888	CbGeAlD
Bortezomib—PSMD2—vagina—uterine cancer	0.00104	0.00882	CbGeAlD
Bortezomib—PSMB8—female gonad—uterine cancer	0.00104	0.00882	CbGeAlD
Bortezomib—PSMB2—endometrium—uterine cancer	0.00103	0.00882	CbGeAlD
Bortezomib—PSMB8—vagina—uterine cancer	0.00103	0.00877	CbGeAlD
Bortezomib—PSMB1—mammalian vulva—uterine cancer	0.00103	0.00874	CbGeAlD
Bortezomib—PSMB2—mammalian vulva—uterine cancer	0.001	0.00853	CbGeAlD
Bortezomib—SLC31A1—uterine cervix—uterine cancer	0.000991	0.00844	CbGeAlD
Bortezomib—PSMB1—uterus—uterine cancer	0.000977	0.00833	CbGeAlD
Bortezomib—PSMB2—uterus—uterine cancer	0.000954	0.00812	CbGeAlD
Bortezomib—CTSG—lymph node—uterine cancer	0.000938	0.00799	CbGeAlD
Bortezomib—SLC31A1—renal system—uterine cancer	0.000927	0.0079	CbGeAlD
Bortezomib—PSMB5—female gonad—uterine cancer	0.000915	0.00779	CbGeAlD
Bortezomib—PSMB5—vagina—uterine cancer	0.000909	0.00775	CbGeAlD
Bortezomib—PSMA1—lymph node—uterine cancer	0.000901	0.00767	CbGeAlD
Bortezomib—SLC31A1—endometrium—uterine cancer	0.000896	0.00764	CbGeAlD
Bortezomib—PSMB1—female reproductive system—uterine cancer	0.000879	0.00749	CbGeAlD
Bortezomib—SLC31A1—mammalian vulva—uterine cancer	0.000867	0.00739	CbGeAlD
Bortezomib—PSMB2—female reproductive system—uterine cancer	0.000857	0.0073	CbGeAlD
Bortezomib—PSMB8—Medrysone—Medroxyprogesterone Acetate—uterine cancer	0.000823	0.197	CbGdCrCtD
Bortezomib—PSMB1—female gonad—uterine cancer	0.0008	0.00681	CbGeAlD
Bortezomib—PSMB1—vagina—uterine cancer	0.000795	0.00677	CbGeAlD
Bortezomib—PTGS1—artery—uterine cancer	0.000786	0.0067	CbGeAlD
Bortezomib—PSMB2—female gonad—uterine cancer	0.00078	0.00665	CbGeAlD
Bortezomib—PSMB2—vagina—uterine cancer	0.000775	0.00661	CbGeAlD
Bortezomib—PSMD1—lymph node—uterine cancer	0.000756	0.00644	CbGeAlD
Bortezomib—SLC31A1—female reproductive system—uterine cancer	0.000742	0.00633	CbGeAlD
Bortezomib—PSMB8—Medrysone—Progesterone—uterine cancer	0.000717	0.172	CbGdCrCtD
Bortezomib—SLC31A1—female gonad—uterine cancer	0.000676	0.00576	CbGeAlD
Bortezomib—SLC31A1—vagina—uterine cancer	0.000671	0.00572	CbGeAlD
Bortezomib—PSMD2—lymph node—uterine cancer	0.00067	0.00571	CbGeAlD
Bortezomib—PSMB8—lymph node—uterine cancer	0.000666	0.00567	CbGeAlD
Bortezomib—PSMB8—Podofilox—Etoposide—uterine cancer	0.000646	0.155	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Medroxyprogesterone Acetate—uterine cancer	0.000596	0.143	CbGdCrCtD
Bortezomib—PSMB5—lymph node—uterine cancer	0.000588	0.00501	CbGeAlD
Bortezomib—PSMB1—lymph node—uterine cancer	0.000514	0.00438	CbGeAlD
Bortezomib—PSMB2—lymph node—uterine cancer	0.000502	0.00427	CbGeAlD
Bortezomib—PSMB8—Testosterone Propionate—Medroxyprogesterone Acetate—uterine cancer	0.000459	0.11	CbGdCrCtD
Bortezomib—SLC31A1—lymph node—uterine cancer	0.000434	0.0037	CbGeAlD
Bortezomib—PSMB8—Testosterone Propionate—Progesterone—uterine cancer	0.0004	0.0957	CbGdCrCtD
Bortezomib—CYP2C8—renal system—uterine cancer	0.000341	0.00291	CbGeAlD
Bortezomib—CYP1A1—epithelium—uterine cancer	0.000339	0.00289	CbGeAlD
Bortezomib—CYP1A1—uterine cervix—uterine cancer	0.000337	0.00287	CbGeAlD
Bortezomib—CYP2C8—endometrium—uterine cancer	0.00033	0.00281	CbGeAlD
Bortezomib—CYP1A2—renal system—uterine cancer	0.000319	0.00272	CbGeAlD
Bortezomib—CYP1A1—renal system—uterine cancer	0.000315	0.00268	CbGeAlD
Bortezomib—PSMB8—Norethindrone—Progesterone—uterine cancer	0.000299	0.0717	CbGdCrCtD
Bortezomib—PTGS1—epithelium—uterine cancer	0.000298	0.00254	CbGeAlD
Bortezomib—PTGS1—uterine cervix—uterine cancer	0.000296	0.00252	CbGeAlD
Bortezomib—CYP1A1—mammalian vulva—uterine cancer	0.000294	0.00251	CbGeAlD
Bortezomib—PTGS1—smooth muscle tissue—uterine cancer	0.000287	0.00245	CbGeAlD
Bortezomib—CYP2C19—vagina—uterine cancer	0.000283	0.00241	CbGeAlD
Bortezomib—CYP1A1—uterus—uterine cancer	0.000281	0.00239	CbGeAlD
Bortezomib—PTGS1—renal system—uterine cancer	0.000277	0.00236	CbGeAlD
Bortezomib—CYP2C8—female reproductive system—uterine cancer	0.000273	0.00233	CbGeAlD
Bortezomib—PTGS1—endometrium—uterine cancer	0.000267	0.00228	CbGeAlD
Bortezomib—PTGS1—mammalian vulva—uterine cancer	0.000259	0.0022	CbGeAlD
Bortezomib—CYP1A1—female reproductive system—uterine cancer	0.000252	0.00215	CbGeAlD
Bortezomib—CYP2C8—vagina—uterine cancer	0.000247	0.0021	CbGeAlD
Bortezomib—PTGS1—uterus—uterine cancer	0.000246	0.0021	CbGeAlD
Bortezomib—CYP2C9—female reproductive system—uterine cancer	0.000243	0.00207	CbGeAlD
Bortezomib—PSMB8—Levonorgestrel—Progesterone—uterine cancer	0.000238	0.057	CbGdCrCtD
Bortezomib—CYP3A4—renal system—uterine cancer	0.000231	0.00197	CbGeAlD
Bortezomib—CYP1A1—female gonad—uterine cancer	0.000229	0.00195	CbGeAlD
Bortezomib—CYP1A1—vagina—uterine cancer	0.000228	0.00194	CbGeAlD
Bortezomib—CYP2D6—renal system—uterine cancer	0.000227	0.00194	CbGeAlD
Bortezomib—PTGS1—female reproductive system—uterine cancer	0.000222	0.00189	CbGeAlD
Bortezomib—PTGS1—female gonad—uterine cancer	0.000202	0.00172	CbGeAlD
Bortezomib—PTGS1—vagina—uterine cancer	0.0002	0.00171	CbGeAlD
Bortezomib—CYP3A4—female reproductive system—uterine cancer	0.000185	0.00158	CbGeAlD
Bortezomib—CYP2D6—female reproductive system—uterine cancer	0.000182	0.00155	CbGeAlD
Bortezomib—CYP2D6—female gonad—uterine cancer	0.000166	0.00141	CbGeAlD
Bortezomib—CYP1A1—lymph node—uterine cancer	0.000148	0.00126	CbGeAlD
Bortezomib—PTGS1—lymph node—uterine cancer	0.00013	0.0011	CbGeAlD
Bortezomib—Hypokalaemia—Doxorubicin—uterine cancer	6.6e-05	0.000328	CcSEcCtD
Bortezomib—Angina pectoris—Epirubicin—uterine cancer	6.6e-05	0.000328	CcSEcCtD
Bortezomib—Breast disorder—Doxorubicin—uterine cancer	6.55e-05	0.000326	CcSEcCtD
Bortezomib—Anorexia—Etoposide—uterine cancer	6.55e-05	0.000326	CcSEcCtD
Bortezomib—Toxic epidermal necrolysis—Doxorubicin—uterine cancer	6.53e-05	0.000325	CcSEcCtD
Bortezomib—Bronchitis—Epirubicin—uterine cancer	6.51e-05	0.000324	CcSEcCtD
Bortezomib—Diarrhoea—Dactinomycin—uterine cancer	6.49e-05	0.000323	CcSEcCtD
Bortezomib—Nasopharyngitis—Doxorubicin—uterine cancer	6.48e-05	0.000322	CcSEcCtD
Bortezomib—Pancytopenia—Epirubicin—uterine cancer	6.43e-05	0.00032	CcSEcCtD
Bortezomib—Hypotension—Etoposide—uterine cancer	6.42e-05	0.000319	CcSEcCtD
Bortezomib—Gastritis—Doxorubicin—uterine cancer	6.42e-05	0.000319	CcSEcCtD
Bortezomib—Muscular weakness—Doxorubicin—uterine cancer	6.39e-05	0.000318	CcSEcCtD
Bortezomib—Neutropenia—Epirubicin—uterine cancer	6.33e-05	0.000315	CcSEcCtD
Bortezomib—Abdominal distension—Doxorubicin—uterine cancer	6.31e-05	0.000314	CcSEcCtD
Bortezomib—Upper respiratory tract infection—Epirubicin—uterine cancer	6.29e-05	0.000313	CcSEcCtD
Bortezomib—Dysphagia—Doxorubicin—uterine cancer	6.27e-05	0.000312	CcSEcCtD
Bortezomib—Influenza—Doxorubicin—uterine cancer	6.27e-05	0.000312	CcSEcCtD
Bortezomib—Pollakiuria—Epirubicin—uterine cancer	6.26e-05	0.000311	CcSEcCtD
Bortezomib—Photosensitivity reaction—Epirubicin—uterine cancer	6.18e-05	0.000307	CcSEcCtD
Bortezomib—Paraesthesia—Etoposide—uterine cancer	6.17e-05	0.000307	CcSEcCtD
Bortezomib—Weight increased—Epirubicin—uterine cancer	6.16e-05	0.000306	CcSEcCtD
Bortezomib—Pancreatitis—Doxorubicin—uterine cancer	6.14e-05	0.000305	CcSEcCtD
Bortezomib—Weight decreased—Epirubicin—uterine cancer	6.13e-05	0.000305	CcSEcCtD
Bortezomib—Dyspnoea—Etoposide—uterine cancer	6.12e-05	0.000305	CcSEcCtD
Bortezomib—Hyperglycaemia—Epirubicin—uterine cancer	6.11e-05	0.000304	CcSEcCtD
Bortezomib—Angina pectoris—Doxorubicin—uterine cancer	6.1e-05	0.000304	CcSEcCtD
Bortezomib—Pneumonia—Epirubicin—uterine cancer	6.07e-05	0.000302	CcSEcCtD
Bortezomib—Infestation NOS—Epirubicin—uterine cancer	6.04e-05	0.0003	CcSEcCtD
Bortezomib—Infestation—Epirubicin—uterine cancer	6.04e-05	0.0003	CcSEcCtD
Bortezomib—Vomiting—Dactinomycin—uterine cancer	6.04e-05	0.0003	CcSEcCtD
Bortezomib—Bronchitis—Doxorubicin—uterine cancer	6.03e-05	0.0003	CcSEcCtD
Bortezomib—Stevens-Johnson syndrome—Epirubicin—uterine cancer	5.99e-05	0.000298	CcSEcCtD
Bortezomib—Rash—Dactinomycin—uterine cancer	5.98e-05	0.000298	CcSEcCtD
Bortezomib—Decreased appetite—Etoposide—uterine cancer	5.97e-05	0.000297	CcSEcCtD
Bortezomib—Pancytopenia—Doxorubicin—uterine cancer	5.95e-05	0.000296	CcSEcCtD
Bortezomib—Renal failure—Epirubicin—uterine cancer	5.94e-05	0.000295	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Etoposide—uterine cancer	5.93e-05	0.000295	CcSEcCtD
Bortezomib—Fatigue—Etoposide—uterine cancer	5.92e-05	0.000295	CcSEcCtD
Bortezomib—Neuropathy peripheral—Epirubicin—uterine cancer	5.92e-05	0.000294	CcSEcCtD
Bortezomib—Stomatitis—Epirubicin—uterine cancer	5.89e-05	0.000293	CcSEcCtD
Bortezomib—Pain—Etoposide—uterine cancer	5.87e-05	0.000292	CcSEcCtD
Bortezomib—Constipation—Etoposide—uterine cancer	5.87e-05	0.000292	CcSEcCtD
Bortezomib—Conjunctivitis—Epirubicin—uterine cancer	5.87e-05	0.000292	CcSEcCtD
Bortezomib—Urinary tract infection—Epirubicin—uterine cancer	5.87e-05	0.000292	CcSEcCtD
Bortezomib—Neutropenia—Doxorubicin—uterine cancer	5.86e-05	0.000291	CcSEcCtD
Bortezomib—Upper respiratory tract infection—Doxorubicin—uterine cancer	5.82e-05	0.00029	CcSEcCtD
Bortezomib—Pollakiuria—Doxorubicin—uterine cancer	5.79e-05	0.000288	CcSEcCtD
Bortezomib—Haematuria—Epirubicin—uterine cancer	5.76e-05	0.000286	CcSEcCtD
Bortezomib—Photosensitivity reaction—Doxorubicin—uterine cancer	5.72e-05	0.000284	CcSEcCtD
Bortezomib—Hepatobiliary disease—Epirubicin—uterine cancer	5.71e-05	0.000284	CcSEcCtD
Bortezomib—Weight increased—Doxorubicin—uterine cancer	5.7e-05	0.000284	CcSEcCtD
Bortezomib—Epistaxis—Epirubicin—uterine cancer	5.69e-05	0.000283	CcSEcCtD
Bortezomib—Weight decreased—Doxorubicin—uterine cancer	5.67e-05	0.000282	CcSEcCtD
Bortezomib—Sinusitis—Epirubicin—uterine cancer	5.66e-05	0.000282	CcSEcCtD
Bortezomib—Feeling abnormal—Etoposide—uterine cancer	5.66e-05	0.000282	CcSEcCtD
Bortezomib—Hyperglycaemia—Doxorubicin—uterine cancer	5.65e-05	0.000281	CcSEcCtD
Bortezomib—Nausea—Dactinomycin—uterine cancer	5.64e-05	0.00028	CcSEcCtD
Bortezomib—Pneumonia—Doxorubicin—uterine cancer	5.62e-05	0.000279	CcSEcCtD
Bortezomib—Gastrointestinal pain—Etoposide—uterine cancer	5.62e-05	0.000279	CcSEcCtD
Bortezomib—Infestation NOS—Doxorubicin—uterine cancer	5.59e-05	0.000278	CcSEcCtD
Bortezomib—Infestation—Doxorubicin—uterine cancer	5.59e-05	0.000278	CcSEcCtD
Bortezomib—Stevens-Johnson syndrome—Doxorubicin—uterine cancer	5.54e-05	0.000275	CcSEcCtD
Bortezomib—Bradycardia—Epirubicin—uterine cancer	5.52e-05	0.000274	CcSEcCtD
Bortezomib—Renal failure—Doxorubicin—uterine cancer	5.49e-05	0.000273	CcSEcCtD
Bortezomib—Neuropathy peripheral—Doxorubicin—uterine cancer	5.48e-05	0.000272	CcSEcCtD
Bortezomib—Urticaria—Etoposide—uterine cancer	5.46e-05	0.000271	CcSEcCtD
Bortezomib—Haemoglobin—Epirubicin—uterine cancer	5.45e-05	0.000271	CcSEcCtD
Bortezomib—Stomatitis—Doxorubicin—uterine cancer	5.45e-05	0.000271	CcSEcCtD
Bortezomib—Abdominal pain—Etoposide—uterine cancer	5.43e-05	0.00027	CcSEcCtD
Bortezomib—Body temperature increased—Etoposide—uterine cancer	5.43e-05	0.00027	CcSEcCtD
Bortezomib—Conjunctivitis—Doxorubicin—uterine cancer	5.43e-05	0.00027	CcSEcCtD
Bortezomib—Urinary tract infection—Doxorubicin—uterine cancer	5.43e-05	0.00027	CcSEcCtD
Bortezomib—Haemorrhage—Epirubicin—uterine cancer	5.42e-05	0.00027	CcSEcCtD
Bortezomib—Hepatitis—Epirubicin—uterine cancer	5.42e-05	0.00027	CcSEcCtD
Bortezomib—Hypoaesthesia—Epirubicin—uterine cancer	5.39e-05	0.000268	CcSEcCtD
Bortezomib—Urinary tract disorder—Epirubicin—uterine cancer	5.35e-05	0.000266	CcSEcCtD
Bortezomib—Oedema peripheral—Epirubicin—uterine cancer	5.34e-05	0.000266	CcSEcCtD
Bortezomib—Haematuria—Doxorubicin—uterine cancer	5.33e-05	0.000265	CcSEcCtD
Bortezomib—Connective tissue disorder—Epirubicin—uterine cancer	5.33e-05	0.000265	CcSEcCtD
Bortezomib—Urethral disorder—Epirubicin—uterine cancer	5.31e-05	0.000264	CcSEcCtD
Bortezomib—Hepatobiliary disease—Doxorubicin—uterine cancer	5.28e-05	0.000263	CcSEcCtD
Bortezomib—Epistaxis—Doxorubicin—uterine cancer	5.27e-05	0.000262	CcSEcCtD
Bortezomib—Sinusitis—Doxorubicin—uterine cancer	5.24e-05	0.000261	CcSEcCtD
Bortezomib—Visual impairment—Epirubicin—uterine cancer	5.22e-05	0.00026	CcSEcCtD
Bortezomib—Erythema multiforme—Epirubicin—uterine cancer	5.12e-05	0.000255	CcSEcCtD
Bortezomib—Bradycardia—Doxorubicin—uterine cancer	5.11e-05	0.000254	CcSEcCtD
Bortezomib—Eye disorder—Epirubicin—uterine cancer	5.07e-05	0.000252	CcSEcCtD
Bortezomib—Hypersensitivity—Etoposide—uterine cancer	5.06e-05	0.000252	CcSEcCtD
Bortezomib—Tinnitus—Epirubicin—uterine cancer	5.05e-05	0.000251	CcSEcCtD
Bortezomib—Haemoglobin—Doxorubicin—uterine cancer	5.04e-05	0.000251	CcSEcCtD
Bortezomib—Cardiac disorder—Epirubicin—uterine cancer	5.03e-05	0.00025	CcSEcCtD
Bortezomib—Flushing—Epirubicin—uterine cancer	5.03e-05	0.00025	CcSEcCtD
Bortezomib—Hepatitis—Doxorubicin—uterine cancer	5.02e-05	0.000249	CcSEcCtD
Bortezomib—Haemorrhage—Doxorubicin—uterine cancer	5.02e-05	0.000249	CcSEcCtD
Bortezomib—Hypoaesthesia—Doxorubicin—uterine cancer	4.99e-05	0.000248	CcSEcCtD
Bortezomib—Urinary tract disorder—Doxorubicin—uterine cancer	4.95e-05	0.000246	CcSEcCtD
Bortezomib—Oedema peripheral—Doxorubicin—uterine cancer	4.94e-05	0.000246	CcSEcCtD
Bortezomib—Asthenia—Etoposide—uterine cancer	4.93e-05	0.000245	CcSEcCtD
Bortezomib—Connective tissue disorder—Doxorubicin—uterine cancer	4.93e-05	0.000245	CcSEcCtD
Bortezomib—Angiopathy—Epirubicin—uterine cancer	4.92e-05	0.000245	CcSEcCtD
Bortezomib—Urethral disorder—Doxorubicin—uterine cancer	4.92e-05	0.000244	CcSEcCtD
Bortezomib—Immune system disorder—Epirubicin—uterine cancer	4.9e-05	0.000243	CcSEcCtD
Bortezomib—Mediastinal disorder—Epirubicin—uterine cancer	4.88e-05	0.000243	CcSEcCtD
Bortezomib—Chills—Epirubicin—uterine cancer	4.86e-05	0.000242	CcSEcCtD
Bortezomib—Pruritus—Etoposide—uterine cancer	4.86e-05	0.000242	CcSEcCtD
Bortezomib—Arrhythmia—Epirubicin—uterine cancer	4.84e-05	0.000241	CcSEcCtD
Bortezomib—Visual impairment—Doxorubicin—uterine cancer	4.83e-05	0.00024	CcSEcCtD
Bortezomib—Mental disorder—Epirubicin—uterine cancer	4.75e-05	0.000236	CcSEcCtD
Bortezomib—Erythema multiforme—Doxorubicin—uterine cancer	4.74e-05	0.000236	CcSEcCtD
Bortezomib—Malnutrition—Epirubicin—uterine cancer	4.72e-05	0.000235	CcSEcCtD
Bortezomib—Erythema—Epirubicin—uterine cancer	4.72e-05	0.000235	CcSEcCtD
Bortezomib—Diarrhoea—Etoposide—uterine cancer	4.7e-05	0.000234	CcSEcCtD
Bortezomib—Eye disorder—Doxorubicin—uterine cancer	4.69e-05	0.000233	CcSEcCtD
Bortezomib—Tinnitus—Doxorubicin—uterine cancer	4.68e-05	0.000233	CcSEcCtD
Bortezomib—Cardiac disorder—Doxorubicin—uterine cancer	4.65e-05	0.000231	CcSEcCtD
Bortezomib—Flushing—Doxorubicin—uterine cancer	4.65e-05	0.000231	CcSEcCtD
Bortezomib—Flatulence—Epirubicin—uterine cancer	4.65e-05	0.000231	CcSEcCtD
Bortezomib—Dysgeusia—Epirubicin—uterine cancer	4.62e-05	0.00023	CcSEcCtD
Bortezomib—Back pain—Epirubicin—uterine cancer	4.56e-05	0.000227	CcSEcCtD
Bortezomib—Angiopathy—Doxorubicin—uterine cancer	4.55e-05	0.000226	CcSEcCtD
Bortezomib—Dizziness—Etoposide—uterine cancer	4.54e-05	0.000226	CcSEcCtD
Bortezomib—Muscle spasms—Epirubicin—uterine cancer	4.54e-05	0.000226	CcSEcCtD
Bortezomib—Immune system disorder—Doxorubicin—uterine cancer	4.53e-05	0.000225	CcSEcCtD
Bortezomib—Mediastinal disorder—Doxorubicin—uterine cancer	4.52e-05	0.000225	CcSEcCtD
Bortezomib—Chills—Doxorubicin—uterine cancer	4.5e-05	0.000224	CcSEcCtD
Bortezomib—Arrhythmia—Doxorubicin—uterine cancer	4.48e-05	0.000223	CcSEcCtD
Bortezomib—Vision blurred—Epirubicin—uterine cancer	4.45e-05	0.000221	CcSEcCtD
Bortezomib—Mental disorder—Doxorubicin—uterine cancer	4.39e-05	0.000218	CcSEcCtD
Bortezomib—Ill-defined disorder—Epirubicin—uterine cancer	4.38e-05	0.000218	CcSEcCtD
Bortezomib—Vomiting—Etoposide—uterine cancer	4.37e-05	0.000217	CcSEcCtD
Bortezomib—Erythema—Doxorubicin—uterine cancer	4.37e-05	0.000217	CcSEcCtD
Bortezomib—Malnutrition—Doxorubicin—uterine cancer	4.37e-05	0.000217	CcSEcCtD
Bortezomib—Anaemia—Epirubicin—uterine cancer	4.36e-05	0.000217	CcSEcCtD
Bortezomib—Agitation—Epirubicin—uterine cancer	4.34e-05	0.000216	CcSEcCtD
Bortezomib—Rash—Etoposide—uterine cancer	4.33e-05	0.000215	CcSEcCtD
Bortezomib—Dermatitis—Etoposide—uterine cancer	4.33e-05	0.000215	CcSEcCtD
Bortezomib—Headache—Etoposide—uterine cancer	4.3e-05	0.000214	CcSEcCtD
Bortezomib—Flatulence—Doxorubicin—uterine cancer	4.3e-05	0.000214	CcSEcCtD
Bortezomib—Dysgeusia—Doxorubicin—uterine cancer	4.28e-05	0.000213	CcSEcCtD
Bortezomib—Malaise—Epirubicin—uterine cancer	4.25e-05	0.000212	CcSEcCtD
Bortezomib—Vertigo—Epirubicin—uterine cancer	4.24e-05	0.000211	CcSEcCtD
Bortezomib—Syncope—Epirubicin—uterine cancer	4.23e-05	0.00021	CcSEcCtD
Bortezomib—Leukopenia—Epirubicin—uterine cancer	4.22e-05	0.00021	CcSEcCtD
Bortezomib—Back pain—Doxorubicin—uterine cancer	4.22e-05	0.00021	CcSEcCtD
Bortezomib—Muscle spasms—Doxorubicin—uterine cancer	4.2e-05	0.000209	CcSEcCtD
Bortezomib—Palpitations—Epirubicin—uterine cancer	4.17e-05	0.000207	CcSEcCtD
Bortezomib—Loss of consciousness—Epirubicin—uterine cancer	4.15e-05	0.000206	CcSEcCtD
Bortezomib—Cough—Epirubicin—uterine cancer	4.12e-05	0.000205	CcSEcCtD
Bortezomib—Vision blurred—Doxorubicin—uterine cancer	4.11e-05	0.000205	CcSEcCtD
Bortezomib—Convulsion—Epirubicin—uterine cancer	4.09e-05	0.000203	CcSEcCtD
Bortezomib—Nausea—Etoposide—uterine cancer	4.08e-05	0.000203	CcSEcCtD
Bortezomib—Hypertension—Epirubicin—uterine cancer	4.07e-05	0.000203	CcSEcCtD
Bortezomib—Ill-defined disorder—Doxorubicin—uterine cancer	4.05e-05	0.000201	CcSEcCtD
Bortezomib—Anaemia—Doxorubicin—uterine cancer	4.04e-05	0.000201	CcSEcCtD
Bortezomib—Myalgia—Epirubicin—uterine cancer	4.02e-05	0.0002	CcSEcCtD
Bortezomib—Arthralgia—Epirubicin—uterine cancer	4.02e-05	0.0002	CcSEcCtD
Bortezomib—Chest pain—Epirubicin—uterine cancer	4.02e-05	0.0002	CcSEcCtD
Bortezomib—Agitation—Doxorubicin—uterine cancer	4.01e-05	0.0002	CcSEcCtD
Bortezomib—Anxiety—Epirubicin—uterine cancer	4e-05	0.000199	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	3.99e-05	0.000198	CcSEcCtD
Bortezomib—Discomfort—Epirubicin—uterine cancer	3.97e-05	0.000197	CcSEcCtD
Bortezomib—Malaise—Doxorubicin—uterine cancer	3.94e-05	0.000196	CcSEcCtD
Bortezomib—Vertigo—Doxorubicin—uterine cancer	3.92e-05	0.000195	CcSEcCtD
Bortezomib—Syncope—Doxorubicin—uterine cancer	3.92e-05	0.000195	CcSEcCtD
Bortezomib—Leukopenia—Doxorubicin—uterine cancer	3.91e-05	0.000194	CcSEcCtD
Bortezomib—Confusional state—Epirubicin—uterine cancer	3.88e-05	0.000193	CcSEcCtD
Bortezomib—Palpitations—Doxorubicin—uterine cancer	3.86e-05	0.000192	CcSEcCtD
Bortezomib—Anaphylactic shock—Epirubicin—uterine cancer	3.85e-05	0.000191	CcSEcCtD
Bortezomib—Oedema—Epirubicin—uterine cancer	3.85e-05	0.000191	CcSEcCtD
Bortezomib—Loss of consciousness—Doxorubicin—uterine cancer	3.84e-05	0.000191	CcSEcCtD
Bortezomib—Infection—Epirubicin—uterine cancer	3.83e-05	0.00019	CcSEcCtD
Bortezomib—Cough—Doxorubicin—uterine cancer	3.81e-05	0.000189	CcSEcCtD
Bortezomib—Shock—Epirubicin—uterine cancer	3.79e-05	0.000188	CcSEcCtD
Bortezomib—Convulsion—Doxorubicin—uterine cancer	3.78e-05	0.000188	CcSEcCtD
Bortezomib—Nervous system disorder—Epirubicin—uterine cancer	3.78e-05	0.000188	CcSEcCtD
Bortezomib—Thrombocytopenia—Epirubicin—uterine cancer	3.77e-05	0.000187	CcSEcCtD
Bortezomib—Hypertension—Doxorubicin—uterine cancer	3.77e-05	0.000187	CcSEcCtD
Bortezomib—Tachycardia—Epirubicin—uterine cancer	3.76e-05	0.000187	CcSEcCtD
Bortezomib—Skin disorder—Epirubicin—uterine cancer	3.74e-05	0.000186	CcSEcCtD
Bortezomib—Hyperhidrosis—Epirubicin—uterine cancer	3.72e-05	0.000185	CcSEcCtD
Bortezomib—Chest pain—Doxorubicin—uterine cancer	3.72e-05	0.000185	CcSEcCtD
Bortezomib—Myalgia—Doxorubicin—uterine cancer	3.72e-05	0.000185	CcSEcCtD
Bortezomib—Arthralgia—Doxorubicin—uterine cancer	3.72e-05	0.000185	CcSEcCtD
Bortezomib—Anxiety—Doxorubicin—uterine cancer	3.7e-05	0.000184	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	3.69e-05	0.000184	CcSEcCtD
Bortezomib—Discomfort—Doxorubicin—uterine cancer	3.67e-05	0.000183	CcSEcCtD
Bortezomib—Anorexia—Epirubicin—uterine cancer	3.67e-05	0.000183	CcSEcCtD
Bortezomib—Hypotension—Epirubicin—uterine cancer	3.6e-05	0.000179	CcSEcCtD
Bortezomib—Confusional state—Doxorubicin—uterine cancer	3.59e-05	0.000179	CcSEcCtD
Bortezomib—Oedema—Doxorubicin—uterine cancer	3.56e-05	0.000177	CcSEcCtD
Bortezomib—Anaphylactic shock—Doxorubicin—uterine cancer	3.56e-05	0.000177	CcSEcCtD
Bortezomib—Infection—Doxorubicin—uterine cancer	3.54e-05	0.000176	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Epirubicin—uterine cancer	3.51e-05	0.000174	CcSEcCtD
Bortezomib—Shock—Doxorubicin—uterine cancer	3.51e-05	0.000174	CcSEcCtD
Bortezomib—Nervous system disorder—Doxorubicin—uterine cancer	3.49e-05	0.000174	CcSEcCtD
Bortezomib—Thrombocytopenia—Doxorubicin—uterine cancer	3.49e-05	0.000173	CcSEcCtD
Bortezomib—Insomnia—Epirubicin—uterine cancer	3.48e-05	0.000173	CcSEcCtD
Bortezomib—Tachycardia—Doxorubicin—uterine cancer	3.48e-05	0.000173	CcSEcCtD
Bortezomib—Skin disorder—Doxorubicin—uterine cancer	3.46e-05	0.000172	CcSEcCtD
Bortezomib—Paraesthesia—Epirubicin—uterine cancer	3.46e-05	0.000172	CcSEcCtD
Bortezomib—Hyperhidrosis—Doxorubicin—uterine cancer	3.44e-05	0.000171	CcSEcCtD
Bortezomib—Dyspnoea—Epirubicin—uterine cancer	3.43e-05	0.000171	CcSEcCtD
Bortezomib—Anorexia—Doxorubicin—uterine cancer	3.4e-05	0.000169	CcSEcCtD
Bortezomib—Dyspepsia—Epirubicin—uterine cancer	3.39e-05	0.000169	CcSEcCtD
Bortezomib—Decreased appetite—Epirubicin—uterine cancer	3.35e-05	0.000166	CcSEcCtD
Bortezomib—Hypotension—Doxorubicin—uterine cancer	3.33e-05	0.000166	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Epirubicin—uterine cancer	3.32e-05	0.000165	CcSEcCtD
Bortezomib—Fatigue—Epirubicin—uterine cancer	3.32e-05	0.000165	CcSEcCtD
Bortezomib—Constipation—Epirubicin—uterine cancer	3.29e-05	0.000164	CcSEcCtD
Bortezomib—Pain—Epirubicin—uterine cancer	3.29e-05	0.000164	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Doxorubicin—uterine cancer	3.25e-05	0.000161	CcSEcCtD
Bortezomib—Insomnia—Doxorubicin—uterine cancer	3.22e-05	0.00016	CcSEcCtD
Bortezomib—Paraesthesia—Doxorubicin—uterine cancer	3.2e-05	0.000159	CcSEcCtD
Bortezomib—Dyspnoea—Doxorubicin—uterine cancer	3.18e-05	0.000158	CcSEcCtD
Bortezomib—Feeling abnormal—Epirubicin—uterine cancer	3.17e-05	0.000158	CcSEcCtD
Bortezomib—Gastrointestinal pain—Epirubicin—uterine cancer	3.15e-05	0.000157	CcSEcCtD
Bortezomib—Dyspepsia—Doxorubicin—uterine cancer	3.14e-05	0.000156	CcSEcCtD
Bortezomib—Decreased appetite—Doxorubicin—uterine cancer	3.1e-05	0.000154	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Doxorubicin—uterine cancer	3.08e-05	0.000153	CcSEcCtD
Bortezomib—Fatigue—Doxorubicin—uterine cancer	3.07e-05	0.000153	CcSEcCtD
Bortezomib—Urticaria—Epirubicin—uterine cancer	3.06e-05	0.000152	CcSEcCtD
Bortezomib—Constipation—Doxorubicin—uterine cancer	3.05e-05	0.000152	CcSEcCtD
Bortezomib—Pain—Doxorubicin—uterine cancer	3.05e-05	0.000152	CcSEcCtD
Bortezomib—Abdominal pain—Epirubicin—uterine cancer	3.04e-05	0.000151	CcSEcCtD
Bortezomib—Body temperature increased—Epirubicin—uterine cancer	3.04e-05	0.000151	CcSEcCtD
Bortezomib—Feeling abnormal—Doxorubicin—uterine cancer	2.94e-05	0.000146	CcSEcCtD
Bortezomib—Gastrointestinal pain—Doxorubicin—uterine cancer	2.91e-05	0.000145	CcSEcCtD
Bortezomib—Hypersensitivity—Epirubicin—uterine cancer	2.84e-05	0.000141	CcSEcCtD
Bortezomib—Urticaria—Doxorubicin—uterine cancer	2.83e-05	0.000141	CcSEcCtD
Bortezomib—Abdominal pain—Doxorubicin—uterine cancer	2.82e-05	0.00014	CcSEcCtD
Bortezomib—Body temperature increased—Doxorubicin—uterine cancer	2.82e-05	0.00014	CcSEcCtD
Bortezomib—Asthenia—Epirubicin—uterine cancer	2.76e-05	0.000137	CcSEcCtD
Bortezomib—Pruritus—Epirubicin—uterine cancer	2.72e-05	0.000135	CcSEcCtD
Bortezomib—Diarrhoea—Epirubicin—uterine cancer	2.63e-05	0.000131	CcSEcCtD
Bortezomib—Hypersensitivity—Doxorubicin—uterine cancer	2.63e-05	0.000131	CcSEcCtD
Bortezomib—Asthenia—Doxorubicin—uterine cancer	2.56e-05	0.000127	CcSEcCtD
Bortezomib—Dizziness—Epirubicin—uterine cancer	2.55e-05	0.000127	CcSEcCtD
Bortezomib—Pruritus—Doxorubicin—uterine cancer	2.52e-05	0.000125	CcSEcCtD
Bortezomib—Vomiting—Epirubicin—uterine cancer	2.45e-05	0.000122	CcSEcCtD
Bortezomib—Diarrhoea—Doxorubicin—uterine cancer	2.44e-05	0.000121	CcSEcCtD
Bortezomib—Rash—Epirubicin—uterine cancer	2.43e-05	0.000121	CcSEcCtD
Bortezomib—Dermatitis—Epirubicin—uterine cancer	2.43e-05	0.000121	CcSEcCtD
Bortezomib—Headache—Epirubicin—uterine cancer	2.41e-05	0.00012	CcSEcCtD
Bortezomib—Dizziness—Doxorubicin—uterine cancer	2.36e-05	0.000117	CcSEcCtD
Bortezomib—Nausea—Epirubicin—uterine cancer	2.29e-05	0.000114	CcSEcCtD
Bortezomib—Vomiting—Doxorubicin—uterine cancer	2.27e-05	0.000113	CcSEcCtD
Bortezomib—Rash—Doxorubicin—uterine cancer	2.25e-05	0.000112	CcSEcCtD
Bortezomib—Dermatitis—Doxorubicin—uterine cancer	2.24e-05	0.000112	CcSEcCtD
Bortezomib—Headache—Doxorubicin—uterine cancer	2.23e-05	0.000111	CcSEcCtD
Bortezomib—Nausea—Doxorubicin—uterine cancer	2.12e-05	0.000105	CcSEcCtD
Bortezomib—CYP2C8—Metabolism—CYP11A1—uterine cancer	9.67e-06	7.59e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—AKR1C1—uterine cancer	9.66e-06	7.58e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—PTEN—uterine cancer	9.63e-06	7.56e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—RRM2—uterine cancer	9.44e-06	7.41e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—NRAS—uterine cancer	9.39e-06	7.37e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—NRAS—uterine cancer	9.39e-06	7.37e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—NRAS—uterine cancer	9.39e-06	7.37e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—EP300—uterine cancer	9.27e-06	7.28e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—NRAS—uterine cancer	9.25e-06	7.26e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—EP300—uterine cancer	9.23e-06	7.24e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—EP300—uterine cancer	9.18e-06	7.21e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—DCN—uterine cancer	9.17e-06	7.19e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—AKR1C3—uterine cancer	9.14e-06	7.17e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—HRAS—uterine cancer	9.06e-06	7.11e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—HRAS—uterine cancer	9.02e-06	7.08e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—HRAS—uterine cancer	8.98e-06	7.04e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—POLD1—uterine cancer	8.82e-06	6.92e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—PTEN—uterine cancer	8.81e-06	6.91e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—PTEN—uterine cancer	8.81e-06	6.91e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—PTEN—uterine cancer	8.81e-06	6.91e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—VEGFA—uterine cancer	8.78e-06	6.89e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—KRAS—uterine cancer	8.75e-06	6.87e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—KRAS—uterine cancer	8.75e-06	6.87e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—KRAS—uterine cancer	8.75e-06	6.87e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—VEGFA—uterine cancer	8.74e-06	6.86e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—VEGFA—uterine cancer	8.7e-06	6.83e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—PTEN—uterine cancer	8.69e-06	6.82e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—RRM2—uterine cancer	8.68e-06	6.81e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—STAR—uterine cancer	8.68e-06	6.81e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—AKR1B1—uterine cancer	8.68e-06	6.81e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—NRAS—uterine cancer	8.67e-06	6.81e-05	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—AKT1—uterine cancer	8.67e-06	6.8e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—ERBB2—uterine cancer	8.64e-06	6.78e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—ERBB2—uterine cancer	8.64e-06	6.78e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—ERBB2—uterine cancer	8.64e-06	6.78e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CYP11A1—uterine cancer	8.64e-06	6.78e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—NRAS—uterine cancer	8.63e-06	6.77e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—KRAS—uterine cancer	8.63e-06	6.77e-05	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—AKT1—uterine cancer	8.62e-06	6.77e-05	CbGpPWpGaD
Bortezomib—PSMA1—Gene Expression—AKT1—uterine cancer	8.62e-06	6.76e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—RRM2—uterine cancer	8.61e-06	6.76e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—NRAS—uterine cancer	8.59e-06	6.74e-05	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—AKT1—uterine cancer	8.58e-06	6.74e-05	CbGpPWpGaD
Bortezomib—PSMD1—Gene Expression—AKT1—uterine cancer	8.58e-06	6.73e-05	CbGpPWpGaD
Bortezomib—PSMD2—Gene Expression—AKT1—uterine cancer	8.54e-06	6.7e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—ERBB2—uterine cancer	8.52e-06	6.68e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—DCN—uterine cancer	8.43e-06	6.62e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—EP300—uterine cancer	8.4e-06	6.59e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—EP300—uterine cancer	8.4e-06	6.59e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—EP300—uterine cancer	8.4e-06	6.59e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—DCN—uterine cancer	8.36e-06	6.56e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—EP300—uterine cancer	8.29e-06	6.5e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—MTHFR—uterine cancer	8.28e-06	6.5e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—AKR1C1—uterine cancer	8.25e-06	6.48e-05	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—PIK3CA—uterine cancer	8.2e-06	6.44e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CXCL8—uterine cancer	8.19e-06	6.43e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CXCL8—uterine cancer	8.19e-06	6.43e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CXCL8—uterine cancer	8.19e-06	6.43e-05	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—PIK3CA—uterine cancer	8.16e-06	6.41e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—AKR1C3—uterine cancer	8.16e-06	6.4e-05	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—PIK3CA—uterine cancer	8.12e-06	6.38e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—KRAS—uterine cancer	8.08e-06	6.34e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—KRAS—uterine cancer	8.08e-06	6.34e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—KRAS—uterine cancer	8.08e-06	6.34e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CXCL8—uterine cancer	8.08e-06	6.34e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—PIK3CA—uterine cancer	8.04e-06	6.31e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—PIK3CA—uterine cancer	8.04e-06	6.31e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—PIK3CA—uterine cancer	8.04e-06	6.31e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CDKN1B—uterine cancer	8e-06	6.28e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CDKN1B—uterine cancer	8e-06	6.28e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CDKN1B—uterine cancer	8e-06	6.28e-05	CbGpPWpGaD
Bortezomib—PSMA1—Disease—AKT1—uterine cancer	8e-06	6.28e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—KRAS—uterine cancer	7.97e-06	6.25e-05	CbGpPWpGaD
Bortezomib—PSMD1—Disease—AKT1—uterine cancer	7.96e-06	6.25e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CYP11A1—uterine cancer	7.94e-06	6.23e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—PIK3CA—uterine cancer	7.93e-06	6.22e-05	CbGpPWpGaD
Bortezomib—PSMD2—Disease—AKT1—uterine cancer	7.93e-06	6.22e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CDKN1B—uterine cancer	7.89e-06	6.19e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CYP11A1—uterine cancer	7.87e-06	6.18e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—STK11—uterine cancer	7.76e-06	6.09e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CYP19A1—uterine cancer	7.76e-06	6.09e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CTNNB1—uterine cancer	7.56e-06	5.93e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CTNNB1—uterine cancer	7.56e-06	5.93e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CTNNB1—uterine cancer	7.56e-06	5.93e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—AKR1C3—uterine cancer	7.5e-06	5.89e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—KRAS—uterine cancer	7.47e-06	5.86e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CTNNB1—uterine cancer	7.45e-06	5.85e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—HRAS—uterine cancer	7.44e-06	5.84e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—HRAS—uterine cancer	7.44e-06	5.84e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—HRAS—uterine cancer	7.44e-06	5.84e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—AKR1C3—uterine cancer	7.44e-06	5.84e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—KRAS—uterine cancer	7.43e-06	5.83e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—PIK3CA—uterine cancer	7.42e-06	5.82e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—PIK3CA—uterine cancer	7.42e-06	5.82e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—PIK3CA—uterine cancer	7.42e-06	5.82e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—KRAS—uterine cancer	7.39e-06	5.8e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—PTEN—uterine cancer	7.37e-06	5.78e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—PTEN—uterine cancer	7.37e-06	5.78e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—PTEN—uterine cancer	7.37e-06	5.78e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—RRM2—uterine cancer	7.36e-06	5.77e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—HRAS—uterine cancer	7.33e-06	5.75e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—PIK3CA—uterine cancer	7.32e-06	5.74e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	7.3e-06	5.73e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	7.29e-06	5.72e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—PTEN—uterine cancer	7.26e-06	5.7e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—DCN—uterine cancer	7.14e-06	5.6e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CYP19A1—uterine cancer	7.12e-06	5.59e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—STK11—uterine cancer	7.12e-06	5.59e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—EP300—uterine cancer	7.03e-06	5.51e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—EP300—uterine cancer	7.03e-06	5.51e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—EP300—uterine cancer	7.03e-06	5.51e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	6.95e-06	5.45e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—EP300—uterine cancer	6.93e-06	5.44e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—HRAS—uterine cancer	6.87e-06	5.39e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—HRAS—uterine cancer	6.87e-06	5.39e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—HRAS—uterine cancer	6.87e-06	5.39e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—PIK3CA—uterine cancer	6.86e-06	5.38e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—PIK3CA—uterine cancer	6.83e-06	5.36e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—POLD1—uterine cancer	6.81e-06	5.34e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—PIK3CA—uterine cancer	6.79e-06	5.33e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—HRAS—uterine cancer	6.77e-06	5.31e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP11A1—uterine cancer	6.73e-06	5.28e-05	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—AKT1—uterine cancer	6.7e-06	5.26e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	6.68e-06	5.24e-05	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—AKT1—uterine cancer	6.67e-06	5.23e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—VEGFA—uterine cancer	6.66e-06	5.22e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—VEGFA—uterine cancer	6.66e-06	5.22e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—VEGFA—uterine cancer	6.66e-06	5.22e-05	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—AKT1—uterine cancer	6.64e-06	5.21e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TP53—uterine cancer	6.64e-06	5.21e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TP53—uterine cancer	6.6e-06	5.18e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—NRAS—uterine cancer	6.57e-06	5.16e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—NRAS—uterine cancer	6.57e-06	5.16e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—NRAS—uterine cancer	6.57e-06	5.16e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TP53—uterine cancer	6.57e-06	5.16e-05	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—AKT1—uterine cancer	6.57e-06	5.15e-05	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—AKT1—uterine cancer	6.57e-06	5.15e-05	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—AKT1—uterine cancer	6.57e-06	5.15e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—VEGFA—uterine cancer	6.56e-06	5.15e-05	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—AKT1—uterine cancer	6.53e-06	5.12e-05	CbGpPWpGaD
Bortezomib—PSMB1—Gene Expression—AKT1—uterine cancer	6.53e-06	5.12e-05	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—AKT1—uterine cancer	6.53e-06	5.12e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—NRAS—uterine cancer	6.48e-06	5.09e-05	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—AKT1—uterine cancer	6.48e-06	5.08e-05	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—AKT1—uterine cancer	6.44e-06	5.05e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—uterine cancer	6.37e-06	5e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—AKR1C1—uterine cancer	6.37e-06	5e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—AKR1C3—uterine cancer	6.35e-06	4.99e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—STK11—uterine cancer	6.35e-06	4.99e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CYP19A1—uterine cancer	6.35e-06	4.99e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—HRAS—uterine cancer	6.35e-06	4.98e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—HRAS—uterine cancer	6.32e-06	4.96e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—HRAS—uterine cancer	6.29e-06	4.93e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—PIK3CA—uterine cancer	6.22e-06	4.88e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—PIK3CA—uterine cancer	6.22e-06	4.88e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—PIK3CA—uterine cancer	6.22e-06	4.88e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—PIK3CA—uterine cancer	6.13e-06	4.81e-05	CbGpPWpGaD
Bortezomib—PSMB2—Disease—AKT1—uterine cancer	6.06e-06	4.76e-05	CbGpPWpGaD
Bortezomib—PSMB1—Disease—AKT1—uterine cancer	6.06e-06	4.76e-05	CbGpPWpGaD
Bortezomib—PSMB5—Disease—AKT1—uterine cancer	6.06e-06	4.76e-05	CbGpPWpGaD
Bortezomib—PSMB8—Disease—AKT1—uterine cancer	5.98e-06	4.69e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	5.96e-06	4.68e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CYP19A1—uterine cancer	5.84e-06	4.59e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—STK11—uterine cancer	5.84e-06	4.59e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—MTHFR—uterine cancer	5.83e-06	4.58e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—STK11—uterine cancer	5.79e-06	4.55e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CYP19A1—uterine cancer	5.79e-06	4.55e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—EP300—uterine cancer	5.69e-06	4.46e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—RRM2—uterine cancer	5.68e-06	4.46e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—KRAS—uterine cancer	5.66e-06	4.44e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—KRAS—uterine cancer	5.66e-06	4.44e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—KRAS—uterine cancer	5.66e-06	4.44e-05	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—AKT1—uterine cancer	5.6e-06	4.4e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—KRAS—uterine cancer	5.58e-06	4.38e-05	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—AKT1—uterine cancer	5.58e-06	4.38e-05	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—AKT1—uterine cancer	5.55e-06	4.36e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—DCN—uterine cancer	5.51e-06	4.33e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	5.44e-06	4.27e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—MTHFR—uterine cancer	5.35e-06	4.2e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—PIK3CA—uterine cancer	5.2e-06	4.08e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—PIK3CA—uterine cancer	5.2e-06	4.08e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—PIK3CA—uterine cancer	5.2e-06	4.08e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP11A1—uterine cancer	5.19e-06	4.07e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	5.19e-06	4.07e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	5.14e-06	4.03e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—PIK3CA—uterine cancer	5.12e-06	4.02e-05	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—AKT1—uterine cancer	5.08e-06	3.98e-05	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—AKT1—uterine cancer	5.08e-06	3.98e-05	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—AKT1—uterine cancer	5.08e-06	3.98e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TP53—uterine cancer	5.03e-06	3.95e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TP53—uterine cancer	5.03e-06	3.95e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TP53—uterine cancer	5.03e-06	3.95e-05	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—AKT1—uterine cancer	5.01e-06	3.93e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TP53—uterine cancer	4.96e-06	3.89e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—STK11—uterine cancer	4.95e-06	3.88e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CYP19A1—uterine cancer	4.95e-06	3.88e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—AKR1C3—uterine cancer	4.9e-06	3.85e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—HRAS—uterine cancer	4.81e-06	3.77e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—HRAS—uterine cancer	4.81e-06	3.77e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—HRAS—uterine cancer	4.81e-06	3.77e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—MTHFR—uterine cancer	4.77e-06	3.75e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—HRAS—uterine cancer	4.74e-06	3.72e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4.71e-06	3.7e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	4.65e-06	3.65e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PTEN—uterine cancer	4.61e-06	3.61e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	4.43e-06	3.48e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—EP300—uterine cancer	4.39e-06	3.45e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—MTHFR—uterine cancer	4.39e-06	3.45e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—MTHFR—uterine cancer	4.35e-06	3.42e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—AKT1—uterine cancer	4.25e-06	3.33e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—AKT1—uterine cancer	4.25e-06	3.33e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—AKT1—uterine cancer	4.25e-06	3.33e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	4.21e-06	3.3e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—AKT1—uterine cancer	4.19e-06	3.29e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.84e-06	3.01e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—STK11—uterine cancer	3.82e-06	3e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CYP19A1—uterine cancer	3.82e-06	3e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—MTHFR—uterine cancer	3.72e-06	2.92e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.28e-06	2.57e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—PIK3CA—uterine cancer	3.25e-06	2.55e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PTEN—uterine cancer	3.25e-06	2.55e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—EP300—uterine cancer	3.1e-06	2.43e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PTEN—uterine cancer	2.98e-06	2.34e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—MTHFR—uterine cancer	2.87e-06	2.25e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—EP300—uterine cancer	2.84e-06	2.23e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PTEN—uterine cancer	2.66e-06	2.08e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—AKT1—uterine cancer	2.65e-06	2.08e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—EP300—uterine cancer	2.53e-06	1.99e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PTEN—uterine cancer	2.44e-06	1.92e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PTEN—uterine cancer	2.42e-06	1.9e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—EP300—uterine cancer	2.33e-06	1.83e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—EP300—uterine cancer	2.31e-06	1.81e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—PIK3CA—uterine cancer	2.29e-06	1.8e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—PIK3CA—uterine cancer	2.1e-06	1.65e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PTEN—uterine cancer	2.07e-06	1.62e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—EP300—uterine cancer	1.97e-06	1.55e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—PIK3CA—uterine cancer	1.87e-06	1.47e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—AKT1—uterine cancer	1.87e-06	1.47e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—PIK3CA—uterine cancer	1.72e-06	1.35e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—AKT1—uterine cancer	1.71e-06	1.35e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—PIK3CA—uterine cancer	1.71e-06	1.34e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PTEN—uterine cancer	1.6e-06	1.25e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—AKT1—uterine cancer	1.53e-06	1.2e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—EP300—uterine cancer	1.52e-06	1.2e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—PIK3CA—uterine cancer	1.46e-06	1.15e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—AKT1—uterine cancer	1.41e-06	1.1e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—AKT1—uterine cancer	1.4e-06	1.1e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—AKT1—uterine cancer	1.19e-06	9.36e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—PIK3CA—uterine cancer	1.13e-06	8.84e-06	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—AKT1—uterine cancer	9.2e-07	7.22e-06	CbGpPWpGaD
